Few substances have slipped into the American household as quietly as melatonin. Parents who would never dream of giving a child a prescription sedative will dissolve a berry-flavored gummy into warm milk without a second thought. The jar sits in the vitamin aisle rather than behind the pharmacy counter, and that placement is the whole problem: a bioactive hormone regulated as a dietary supplement, not as a drug, has become the default answer to childhood sleeplessness, and its normalization has raced ahead of the science that should govern it.
That is the paradox at the center of an invited commentary published in JAMA Network Open, accompanying a new study of melatonin use and sleep architecture in children who were evaluated at a pediatric sleep laboratory. The commentary’s core argument is a correction of framing: the study’s findings, while reassuring on the surface, do not license routine pediatric use, and the gap between how families use melatonin and what researchers actually know keeps widening.
A supplement that normalized faster than its evidence
The prevalence numbers explain why the commentary was necessary at all. Sleep problems affect roughly one in three children and adolescents worldwide, and the clinical systems built to evaluate and treat pediatric sleep disorders remain thin. Into that gap stepped a supplement with a plausible story: it is natural, it is what the brain makes at night, and it is available without a prescription.
A survey of roughly 1,000 US children aged 1 to 13 found that in the past month, 5.6 percent of preschoolers, 18.5 percent of school-aged children, and 19.4 percent of preteens had taken melatonin. Use doubled between 2017 and 2020. A 2026 systematic review found the same trajectory internationally: use climbing, refills stretching on, benefit concentrated chiefly among children with neurodevelopmental conditions, while trials testing efficacy in typically developing young children are absent and long-term safety data remain thin. In other words, the fastest-growing pediatric sleep intervention in a generation is one that has never been tested for its most common real-world use.
What the sleep lab showed
The companion study brought something rare to this debate: objective measurement. It was a cross-sectional analysis in which 684 children who had been sent to a pediatric sleep laboratory were matched one-to-one on propensity scores, pairing 342 outpatient melatonin users with 342 nonusers. The primary outcome was REM sleep percentage, with 14 additional polysomnographic measures tracked alongside.
Median REM sleep was 16.7 percent in melatonin users versus 19.0 percent in nonusers. The modest reduction held up under several sensitivity analyses, but it shrank and fell below statistical significance once the adjustment came to include psychiatric diagnoses plus any sleep medications taken at the same time. Across the remaining 14 measures, no significant differences emerged.
The commentary credits the study with three contributions. It brings objective polysomnographic evidence to a field often steered by symptoms and caregiver report. It shows that taking melatonin as an outpatient came with no broad disruption of sleep architecture. And it flags REM as a physiologic signal that deserves closer attention.
REM is not a trivial dial
The stakes of that last point are developmental. REM sleep is tied to emotional memory, affective processing, learning, and neurodevelopmental plasticity, the very processes that are most active, and most vulnerable, in childhood. A single night of recording is not enough to determine whether long-term melatonin exposure modifies those processes over time. The small REM difference seen in the study may matter little in a child who used melatonin for two weeks, and quite a lot in a child who has taken it nightly for two years, and the data simply cannot distinguish those cases.
A chronobiotic, not a sedative
The commentary’s central corrective is conceptual. Melatonin is a bioactive chronobiotic, an endogenous molecule that helps set the timing of the sleep-wake cycle, not a catch-all pediatric sedative. Its most defensible use is circadian misalignment, not sleep difficulty in general. A family giving melatonin at 8 p.m. to a child who cannot fall asleep is often addressing the wrong problem, and the framing matters because it determines whether the intervention is ever reviewed, adjusted, or stopped.
That is why the commentary pushes back on reading the study as clearance. A sleep recording that shows no sweeping disruption should not be taken as a green light for routine pediatric use. Instead, use should be phenotype-guided and tailored, not universal.
Behavior first, melatonin as bridge
Behavioral care remains the bedrock of pediatric insomnia treatment. The established toolkit, built on evidence melatonin cannot match because the supplement has been studied mainly in narrow populations, includes a structured bedtime routine, strategies that put parents at the center, stimulus control, sleep scheduling, and cognitive behavioral approaches. Melatonin has a reasonable place as a pragmatic adjunct or bridge when those first-line approaches are insufficient, especially when the diagnosis is a delayed sleep-wake phase disorder, neurodevelopmental sleep-onset insomnia, or selected cases of chronic insomnia. The supplement can serve as a stopgap while the behavioral plan takes effect.
When it is used, every axis should be individualized: the indication, the formulation, the dose, the timing, the duration, the monitoring plan, and the discontinuation strategy, all set alongside sleep behavioral care, review of medications, and monitoring for adverse effects. A gummy handed out nightly with no review, no target symptom, and no exit plan is the opposite of that program.
Implications
The open questions are now sharper. Does melatonin shift only sleep timing, or does it also shape sleep architecture? Do small REM differences matter during development, when the brain is still wiring its emotional and memory systems? And do the effects change depending on circadian phase, dose, timing, formulation, pubertal stage, and neurodevelopmental status? Each is answerable, but none has been answered.
The study’s scientific value, the commentary concludes, lies not in settling the safety question but in reframing the timing, the population, and the developmental conditions under which melatonin might modify the developing sleep system. For parents, the practical translation is less comfortable: the jar in the vitamin aisle is a shortcut that the evidence has not yet earned. The quiet takeover of children’s sleep by a supplement has happened; the science is still catching up, and the REM signal is a reminder that nothing having looked broken is not the same as nothing having happened.
Source
Seixas AA. Melatonin and the Developing Sleep System. JAMA Network Open. 2026;9(8):e2626852. doi:10.1001/jamanetworkopen.2026.26852. PMID: 42560679.
Companion study: Juginovic A, Rodman R. Melatonin Use and Polysomnographic Sleep Architecture in Children. JAMA Network Open. 2026;9(8):e2626983.